Tag: Tricyclic antidepressant (tertiary amine; first synthetic antidepressant)

  • Imipramine

    Tricyclic antidepressant (tertiary amine; first synthetic antidepressant)

    The first synthetic antidepressant; the parent compound of the TCA class and the historical reference for monoamine theory of depression.

    Abstract

    Imipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; CAS 50-49-7; molecular formula C19H24N2; molecular weight 280.41) is a dibenzazepine tertiary amine TCA developed at Geigy by Roland Kuhn in 1958, the first synthetic compound demonstrated to relieve depressive symptoms in clinical trial. The historical observation underpinned the catecholamine hypothesis of depression and launched modern psychopharmacology. SERT and NET affinities are balanced (SERT Ki approximately 1 nM, NET Ki approximately 21 nM); the active metabolite desipramine is a NET-preferring secondary amine. Off-target activity parallels amitriptyline: muscarinic, H1, alpha-1, and sodium channel block. Plasma half-life is 11 to 25 hours; metabolism is via CYP2D6 and CYP2C19. Approved for major depressive disorder; clinical use today focuses on enuresis (bedwetting) in children (low-dose for anticholinergic and alpha-1 effects on bladder) and panic disorder. The TCA cardiotoxicity profile is the principal limitation. Used as the historical reference TCA and the prototype monoamine reuptake inhibitor in pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.